Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
NCT03403465 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2026-02-27
Summary
This study expands on protocol (NCT01908504"PET adaptive RT") designed to evaluate the utility of adaptive PET-CT planning for radiation therapy (RT). Radiation therapy is used in many malignant diseases as a curative treatment modality. However, critical normal tissue is often in close approximation to disease, and portions of such tissue must receive high doses of radiation for appropriate treatment.
Positron Emission Tomography (PET) adapted radiation therapy, as defined in the current protocol, may allow for a means of determining the eventual response to therapy, at a time point when adaptation of treatment plan may be possible to improve outcomes. This protocol will build upon the findings the previous protocol (NCT01908504 "PET adaptive RT") that evaluated the utility of intra-treatment PET imaging in multiple types of cancers. The current focus will be more specific to certain types of gastrointestinal and gynecologic cancers treated with RT, identified from the prior study to warrant further research.
Conditions
- Cancer of the Cervix
- Vulvar Cancer
- Esophageal Cancer
- Anal Canal Cancer
Interventions
- OTHER
-
FDG PET scan
At radiation planning subjects will have a PET-CT. The CT scan - also called computerized tomography or just CT - combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. CT scans in planning radiation therapy are standard of care. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Junzo Chino, MD · Duke University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-03-27
- Primary Completion
- 2028-04-05
- Completion
- 2028-04-05
Countries
- United States
Study Locations
More Related Trials
-
Repeat CT Scans for Evaluation of Inter- and Intrafraction Motion and it's Effect on Radiotherapy Dose Distribution During Curative Radiotherapy for Pelvic Tumours
NCT03022539 ·Status: COMPLETED
-
Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study
NCT00907140 ·Status: COMPLETED ·Phase: NA
-
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
NCT04161781 ·Status: COMPLETED
-
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging
NCT04017104 ·Status: UNKNOWN
-
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
NCT01717391 ·Status: COMPLETED ·Phase: PHASE2
-
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
NCT04750772 ·Status: UNKNOWN ·Phase: NA
-
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies
NCT06644274 ·Status: RECRUITING
-
Positron Emission Tomography in Patients With Breast Cancer
NCT00001385 ·Status: COMPLETED
-
FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer
NCT02317302 ·Status: TERMINATED ·Phase: PHASE1
-
Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer
NCT03442504 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Multimodal PET Imaging in the Diagnosis and Treatment of Pelvic Tumors
NCT06774209 ·Status: RECRUITING ·Phase: NA
-
The Role of FDG PET in Radiation Treatment Planning for Head and Neck Cancers
NCT00230269 ·Status: COMPLETED
-
PET in Guiding Cervical Lymphadenectomy (ECTOP-2003)
NCT03244566 ·Status: COMPLETED
-
MPDL3280A-imaging-IST-UMCG
NCT02453984 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Positron Emission Tomography (PET) During Radio-chemotherapy to Treat Otorhinolaryngological Cancer
NCT02469922 ·Status: COMPLETED ·Phase: NA
-
An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors
NCT04993261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Assessment of Investigational Positron Emission Tomography and Post-Processing Procedures Performed as Add-ons to Standard of Care Imaging
NCT03490812 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
In-Room PET in Proton Radiation Therapy
NCT01228448 ·Status: COMPLETED ·Phase: NA
-
Rectal Cancer: Local Staging, Re-staging and Assessment of Lymph Nodes Using Pet-Ct, CT-Perfusion and 3T MRI
NCT01525056 ·Status: COMPLETED ·Phase: PHASE2
-
Molecular Determinants Affecting Fluoro-L-thymidine (FLT) Positron Emission Tomography (PET) in Rectal Cancer
NCT01207895 ·Status: COMPLETED ·Phase: PHASE1
-
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
NCT03288597 ·Status: UNKNOWN
-
FDG - PET / MRI in Patients With Rectal Cancer
NCT03846882 ·Status: UNKNOWN
-
18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
NCT05531045 ·Status: NOT_YET_RECRUITING
-
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
NCT00019565 ·Status: COMPLETED ·Phase: PHASE1
-
Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer
NCT05088785 ·Status: RECRUITING ·Phase: NA